Share Price and Basic Stock Data
Last Updated: February 7, 2026, 7:21 pm
| PEG Ratio | 14.23 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Hester Biosciences Ltd operates within the pharmaceuticals sector, focusing on veterinary vaccines and biologicals. The company reported a sales figure of ₹266 Cr for the fiscal year ending March 2023, which rose to ₹311 Cr for FY 2025, reflecting a steady revenue growth trend. Quarterly sales showed fluctuations, with the highest sales recorded at ₹88 Cr in June 2023 and the lowest at ₹67 Cr in both March 2023 and December 2023. This indicates a potential seasonality effect or other operational challenges impacting revenue consistency. The trailing twelve months (TTM) sales stood at ₹300 Cr, demonstrating resilience despite market fluctuations. The company’s ability to maintain sales growth aligns well with industry expectations, particularly in a sector that often sees variable demand based on livestock health issues and agricultural cycles.
Profitability and Efficiency Metrics
Hester Biosciences reported a net profit of ₹45 Cr for FY 2025, a slight recovery from ₹28 Cr in FY 2023. The operating profit margin (OPM) for the latest fiscal year stood at 20.88%, reflecting a commendable performance relative to the pharmaceuticals sector’s typical margins. The interest coverage ratio (ICR) of 5.12 times indicates strong operational earnings relative to interest obligations, suggesting effective management of debt. However, the return on equity (ROE) was recorded at 9.18%, which is relatively low compared to industry averages, indicating room for improvement in generating shareholder returns. Additionally, the cash conversion cycle (CCC) of 255 days raises concerns about liquidity and operational efficiency, as it reflects the time taken to convert investments in inventory and other resources into cash flows from sales.
Balance Sheet Strength and Financial Ratios
The balance sheet of Hester Biosciences reveals total borrowings of ₹214 Cr against reserves of ₹329 Cr, signifying a solid equity base relative to debt levels. The total liabilities stood at ₹653 Cr, while total assets were reported at ₹675 Cr, reflecting a healthy asset-to-liability ratio. The price-to-book value (P/BV) ratio of 3.39x indicates that the stock is trading at a premium compared to its book value, which may suggest investor confidence or growth expectations. The current ratio of 1.56x indicates adequate short-term liquidity, although a quick ratio of 0.99x suggests potential challenges in meeting immediate liabilities without relying on inventory sales. Additionally, the company’s return on capital employed (ROCE) was recorded at 9.71%, which is moderate and highlights the need for enhanced capital efficiency to maximize returns.
Shareholding Pattern and Investor Confidence
Hester Biosciences has a stable shareholding pattern, with promoters holding 53.73% of the equity, indicating strong management control and confidence in the company’s future. The foreign institutional investors (FIIs) stake increased slightly to 0.53%, while domestic institutional investors (DIIs) remain absent, suggesting a reliance on retail investor sentiment. The total number of shareholders reported as of September 2025 was 12,260, indicating a diverse investor base. The absence of significant institutional investment may reflect cautious sentiment among larger investors regarding the company’s growth potential or market position. However, the steady promoter holding can be a positive signal for retail investors, indicating alignment of interests between management and shareholders.
Outlook, Risks, and Final Insight
Hester Biosciences faces both opportunities and challenges as it navigates the competitive pharmaceuticals landscape. Strengths include a solid revenue trajectory and a strong promoter holding, which can foster investor confidence. However, risks persist, particularly in the form of fluctuating profit margins and a lengthy cash conversion cycle that could strain liquidity. The potential for growth exists through expanding product lines and improving operational efficiencies. The company must address its lower ROE and moderate ROCE to enhance shareholder value. Moving forward, if Hester can optimize its operational processes and leverage its strong equity base effectively, it may position itself favorably in an evolving market. Conversely, sustained pressure on margins and operational inefficiencies could hinder growth, necessitating focused strategic adjustments.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 128 Cr. | 102 | 185/84.3 | 28.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,527 Cr. | 324 | 479/192 | 73.8 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.0 Cr. | 53.9 | 54.0/17.0 | 188 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,603.60 Cr | 1,093.01 | 42.92 | 202.24 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74.94 | 67.30 | 87.85 | 70.46 | 66.98 | 79.26 | 82.27 | 83.69 | 63.22 | 81.93 | 84.11 | 70.97 | 77.42 |
| Expenses | 56.18 | 55.63 | 73.49 | 57.24 | 56.83 | 63.34 | 64.62 | 64.53 | 58.15 | 62.75 | 61.30 | 59.25 | 59.62 |
| Operating Profit | 18.76 | 11.67 | 14.36 | 13.22 | 10.15 | 15.92 | 17.65 | 19.16 | 5.07 | 19.18 | 22.81 | 11.72 | 17.80 |
| OPM % | 25.03% | 17.34% | 16.35% | 18.76% | 15.15% | 20.09% | 21.45% | 22.89% | 8.02% | 23.41% | 27.12% | 16.51% | 22.99% |
| Other Income | 6.37 | 3.49 | 2.52 | 5.91 | 2.20 | 4.63 | 2.09 | 2.80 | 8.78 | -5.64 | 3.37 | 11.88 | 1.98 |
| Interest | 3.89 | 1.37 | 2.57 | 8.08 | 2.19 | 6.94 | 5.01 | 5.89 | -3.81 | 5.62 | 1.81 | 2.21 | 1.82 |
| Depreciation | 5.24 | 5.37 | 5.40 | 4.28 | 3.75 | 3.74 | 4.13 | 4.20 | 4.29 | 4.18 | 4.18 | 4.35 | 4.43 |
| Profit before tax | 16.00 | 8.42 | 8.91 | 6.77 | 6.41 | 9.87 | 10.60 | 11.87 | 13.37 | 3.74 | 20.19 | 17.04 | 13.53 |
| Tax % | 24.00% | 32.19% | 24.69% | 40.18% | 37.44% | 35.16% | 29.34% | 29.32% | 14.66% | 58.82% | 14.36% | 15.90% | 31.19% |
| Net Profit | 12.16 | 5.71 | 6.71 | 4.04 | 4.02 | 6.40 | 7.49 | 8.39 | 11.41 | 1.54 | 17.29 | 14.33 | 9.32 |
| EPS in Rs | 13.15 | 5.33 | 6.90 | 4.81 | 4.68 | 5.82 | 7.45 | 9.64 | 13.71 | 1.52 | 19.33 | 16.99 | 10.31 |
Last Updated: February 5, 2026, 5:39 pm
Below is a detailed analysis of the quarterly data for Hester Biosciences Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 77.42 Cr.. The value appears strong and on an upward trend. It has increased from 70.97 Cr. (Sep 2025) to 77.42 Cr., marking an increase of 6.45 Cr..
- For Expenses, as of Dec 2025, the value is 59.62 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 59.25 Cr. (Sep 2025) to 59.62 Cr., marking an increase of 0.37 Cr..
- For Operating Profit, as of Dec 2025, the value is 17.80 Cr.. The value appears strong and on an upward trend. It has increased from 11.72 Cr. (Sep 2025) to 17.80 Cr., marking an increase of 6.08 Cr..
- For OPM %, as of Dec 2025, the value is 22.99%. The value appears strong and on an upward trend. It has increased from 16.51% (Sep 2025) to 22.99%, marking an increase of 6.48%.
- For Other Income, as of Dec 2025, the value is 1.98 Cr.. The value appears to be declining and may need further review. It has decreased from 11.88 Cr. (Sep 2025) to 1.98 Cr., marking a decrease of 9.90 Cr..
- For Interest, as of Dec 2025, the value is 1.82 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.21 Cr. (Sep 2025) to 1.82 Cr., marking a decrease of 0.39 Cr..
- For Depreciation, as of Dec 2025, the value is 4.43 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.35 Cr. (Sep 2025) to 4.43 Cr., marking an increase of 0.08 Cr..
- For Profit before tax, as of Dec 2025, the value is 13.53 Cr.. The value appears to be declining and may need further review. It has decreased from 17.04 Cr. (Sep 2025) to 13.53 Cr., marking a decrease of 3.51 Cr..
- For Tax %, as of Dec 2025, the value is 31.19%. The value appears to be increasing, which may not be favorable. It has increased from 15.90% (Sep 2025) to 31.19%, marking an increase of 15.29%.
- For Net Profit, as of Dec 2025, the value is 9.32 Cr.. The value appears to be declining and may need further review. It has decreased from 14.33 Cr. (Sep 2025) to 9.32 Cr., marking a decrease of 5.01 Cr..
- For EPS in Rs, as of Dec 2025, the value is 10.31. The value appears to be declining and may need further review. It has decreased from 16.99 (Sep 2025) to 10.31, marking a decrease of 6.68.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:16 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69 | 90 | 101 | 123 | 136 | 178 | 183 | 214 | 235 | 266 | 305 | 311 | 300 |
| Expenses | 44 | 64 | 67 | 82 | 89 | 110 | 128 | 146 | 175 | 215 | 251 | 250 | 241 |
| Operating Profit | 24 | 25 | 34 | 41 | 47 | 68 | 55 | 69 | 60 | 51 | 54 | 62 | 59 |
| OPM % | 36% | 28% | 34% | 33% | 35% | 38% | 30% | 32% | 26% | 19% | 18% | 20% | 20% |
| Other Income | 1 | 3 | 1 | 0 | 3 | 7 | 6 | 1 | 14 | 20 | 15 | 8 | 18 |
| Interest | 6 | 5 | 4 | 4 | 4 | 7 | 7 | 7 | 4 | 9 | 20 | 13 | 6 |
| Depreciation | 5 | 6 | 6 | 7 | 10 | 12 | 13 | 13 | 17 | 21 | 17 | 17 | 17 |
| Profit before tax | 13 | 18 | 25 | 31 | 36 | 57 | 41 | 50 | 54 | 40 | 32 | 40 | 54 |
| Tax % | 31% | 26% | 23% | 26% | 36% | 28% | 25% | 31% | 26% | 30% | 34% | 27% | |
| Net Profit | 9 | 13 | 19 | 23 | 23 | 41 | 31 | 35 | 39 | 28 | 21 | 29 | 45 |
| EPS in Rs | 11.11 | 15.99 | 22.57 | 27.68 | 30.12 | 48.87 | 34.29 | 40.47 | 46.22 | 31.30 | 22.21 | 32.31 | 51.55 |
| Dividend Payout % | 18% | 19% | 18% | 19% | 33% | 23% | 19% | 25% | 22% | 26% | 27% | 22% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 44.44% | 46.15% | 21.05% | 0.00% | 78.26% | -24.39% | 12.90% | 11.43% | -28.21% | -25.00% | 38.10% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1.71% | -25.10% | -21.05% | 78.26% | -102.65% | 37.29% | -1.47% | -39.63% | 3.21% | 63.10% |
Hester Biosciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -1% |
| 3 Years: | -11% |
| TTM: | 94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 6% |
| 3 Years: | 0% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| Last Year: | 9% |
Last Updated: September 5, 2025, 6:05 am
Balance Sheet
Last Updated: December 4, 2025, 1:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 66 | 76 | 93 | 113 | 132 | 169 | 193 | 220 | 251 | 271 | 283 | 306 | 329 |
| Borrowings | 48 | 55 | 59 | 66 | 69 | 90 | 121 | 110 | 228 | 274 | 244 | 213 | 214 |
| Other Liabilities | 19 | 20 | 25 | 25 | 35 | 32 | 65 | 73 | 74 | 116 | 126 | 126 | 124 |
| Total Liabilities | 142 | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 675 |
| Fixed Assets | 54 | 60 | 65 | 102 | 110 | 145 | 142 | 133 | 237 | 259 | 240 | 233 | 247 |
| CWIP | 21 | 33 | 36 | 21 | 32 | 7 | 74 | 109 | 82 | 149 | 171 | 183 | 182 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 25 | 30 | 34 | 37 |
| Other Assets | 68 | 68 | 85 | 89 | 102 | 148 | 170 | 169 | 222 | 237 | 221 | 203 | 209 |
| Total Assets | 142 | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 675 |
Below is a detailed analysis of the balance sheet data for Hester Biosciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Reserves, as of Sep 2025, the value is 329.00 Cr.. The value appears strong and on an upward trend. It has increased from 306.00 Cr. (Mar 2025) to 329.00 Cr., marking an increase of 23.00 Cr..
- For Borrowings, as of Sep 2025, the value is 214.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 213.00 Cr. (Mar 2025) to 214.00 Cr., marking an increase of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 124.00 Cr.. The value appears to be improving (decreasing). It has decreased from 126.00 Cr. (Mar 2025) to 124.00 Cr., marking a decrease of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 675.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 653.00 Cr. (Mar 2025) to 675.00 Cr., marking an increase of 22.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 233.00 Cr. (Mar 2025) to 247.00 Cr., marking an increase of 14.00 Cr..
- For CWIP, as of Sep 2025, the value is 182.00 Cr.. The value appears to be declining and may need further review. It has decreased from 183.00 Cr. (Mar 2025) to 182.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 37.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Mar 2025) to 37.00 Cr., marking an increase of 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 209.00 Cr.. The value appears strong and on an upward trend. It has increased from 203.00 Cr. (Mar 2025) to 209.00 Cr., marking an increase of 6.00 Cr..
- For Total Assets, as of Sep 2025, the value is 675.00 Cr.. The value appears strong and on an upward trend. It has increased from 653.00 Cr. (Mar 2025) to 675.00 Cr., marking an increase of 22.00 Cr..
Notably, the Reserves (329.00 Cr.) exceed the Borrowings (214.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -24.00 | -30.00 | -25.00 | -25.00 | -22.00 | -22.00 | -66.00 | -41.00 | -168.00 | -223.00 | -190.00 | -151.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 72 | 95 | 79 | 87 | 67 | 116 | 84 | 86 | 109 | 94 | 86 |
| Inventory Days | 1,145 | 431 | 627 | 376 | 505 | 540 | 834 | 452 | 424 | 399 | 288 | 291 |
| Days Payable | 145 | 68 | 109 | 84 | 100 | 93 | 261 | 204 | 101 | 141 | 98 | 122 |
| Cash Conversion Cycle | 1,074 | 434 | 614 | 371 | 491 | 514 | 690 | 332 | 409 | 367 | 284 | 255 |
| Working Capital Days | 36 | 76 | 112 | 90 | 82 | 106 | 104 | 134 | 113 | 88 | 112 | 74 |
| ROCE % | 18% | 15% | 19% | 19% | 20% | 26% | 16% | 18% | 14% | 9% | 9% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 41 | 0.08 | 0.01 | 41 | 2025-04-22 17:25:33 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 33.89 | 24.88 | 32.96 | 46.41 | 40.79 |
| Diluted EPS (Rs.) | 33.89 | 24.88 | 32.96 | 46.41 | 40.79 |
| Cash EPS (Rs.) | 48.82 | 39.65 | 52.10 | 65.41 | 56.44 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 369.41 | 356.03 | 339.19 | 314.32 | 277.37 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 369.41 | 356.03 | 339.19 | 314.32 | 277.37 |
| Revenue From Operations / Share (Rs.) | 365.70 | 357.99 | 312.79 | 276.25 | 251.95 |
| PBDIT / Share (Rs.) | 76.38 | 75.58 | 77.30 | 86.66 | 86.21 |
| PBIT / Share (Rs.) | 56.63 | 55.39 | 52.97 | 67.17 | 70.56 |
| PBT / Share (Rs.) | 41.70 | 32.14 | 42.02 | 62.39 | 58.90 |
| Net Profit / Share (Rs.) | 29.07 | 19.46 | 27.77 | 45.92 | 40.79 |
| NP After MI And SOA / Share (Rs.) | 32.31 | 22.20 | 31.30 | 46.41 | 40.47 |
| PBDIT Margin (%) | 20.88 | 21.11 | 24.71 | 31.37 | 34.21 |
| PBIT Margin (%) | 15.48 | 15.47 | 16.93 | 24.31 | 28.00 |
| PBT Margin (%) | 11.40 | 8.97 | 13.43 | 22.58 | 23.37 |
| Net Profit Margin (%) | 7.94 | 5.43 | 8.87 | 16.62 | 16.18 |
| NP After MI And SOA Margin (%) | 8.83 | 6.20 | 10.00 | 16.80 | 16.06 |
| Return on Networth / Equity (%) | 8.74 | 6.47 | 9.51 | 15.18 | 15.08 |
| Return on Capital Employeed (%) | 9.12 | 8.46 | 8.64 | 12.28 | 17.16 |
| Return On Assets (%) | 4.20 | 2.85 | 3.97 | 7.02 | 8.37 |
| Long Term Debt / Equity (X) | 0.42 | 0.62 | 0.66 | 0.63 | 0.36 |
| Total Debt / Equity (X) | 0.66 | 0.81 | 0.95 | 0.85 | 0.37 |
| Asset Turnover Ratio (%) | 0.47 | 0.45 | 0.43 | 0.52 | 0.62 |
| Current Ratio (X) | 1.56 | 2.03 | 1.53 | 2.01 | 2.63 |
| Quick Ratio (X) | 0.99 | 1.31 | 0.96 | 1.23 | 1.62 |
| Inventory Turnover Ratio (X) | 4.26 | 0.67 | 0.66 | 0.52 | 0.39 |
| Dividend Payout Ratio (NP) (%) | 18.56 | 36.02 | 31.94 | 21.54 | 16.30 |
| Dividend Payout Ratio (CP) (%) | 11.52 | 18.86 | 17.97 | 15.17 | 11.76 |
| Earning Retention Ratio (%) | 81.44 | 63.98 | 68.06 | 78.46 | 83.70 |
| Cash Earning Retention Ratio (%) | 88.48 | 81.14 | 82.03 | 84.83 | 88.24 |
| Interest Coverage Ratio (X) | 5.12 | 3.25 | 7.06 | 18.14 | 11.11 |
| Interest Coverage Ratio (Post Tax) (X) | 2.95 | 1.84 | 3.53 | 10.61 | 6.76 |
| Enterprise Value (Cr.) | 1279.65 | 1416.65 | 1555.60 | 2514.68 | 1703.08 |
| EV / Net Operating Revenue (X) | 4.11 | 4.65 | 5.85 | 10.70 | 7.95 |
| EV / EBITDA (X) | 19.69 | 22.03 | 23.66 | 34.11 | 23.22 |
| MarketCap / Net Operating Revenue (X) | 3.43 | 3.88 | 4.86 | 9.83 | 7.61 |
| Retention Ratios (%) | 81.43 | 63.97 | 68.05 | 78.45 | 83.69 |
| Price / BV (X) | 3.39 | 4.05 | 4.62 | 8.88 | 7.14 |
| Price / Net Operating Revenue (X) | 3.43 | 3.88 | 4.86 | 9.83 | 7.61 |
| EarningsYield | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 |
After reviewing the key financial ratios for Hester Biosciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 33.89. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 33.89, marking an increase of 9.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 33.89. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 33.89, marking an increase of 9.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 48.82. This value is within the healthy range. It has increased from 39.65 (Mar 24) to 48.82, marking an increase of 9.17.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 369.41. It has increased from 356.03 (Mar 24) to 369.41, marking an increase of 13.38.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 369.41. It has increased from 356.03 (Mar 24) to 369.41, marking an increase of 13.38.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 365.70. It has increased from 357.99 (Mar 24) to 365.70, marking an increase of 7.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 76.38. This value is within the healthy range. It has increased from 75.58 (Mar 24) to 76.38, marking an increase of 0.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is 56.63. This value is within the healthy range. It has increased from 55.39 (Mar 24) to 56.63, marking an increase of 1.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 41.70. This value is within the healthy range. It has increased from 32.14 (Mar 24) to 41.70, marking an increase of 9.56.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 29.07. This value is within the healthy range. It has increased from 19.46 (Mar 24) to 29.07, marking an increase of 9.61.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 32.31. This value is within the healthy range. It has increased from 22.20 (Mar 24) to 32.31, marking an increase of 10.11.
- For PBDIT Margin (%), as of Mar 25, the value is 20.88. This value is within the healthy range. It has decreased from 21.11 (Mar 24) to 20.88, marking a decrease of 0.23.
- For PBIT Margin (%), as of Mar 25, the value is 15.48. This value is within the healthy range. It has increased from 15.47 (Mar 24) to 15.48, marking an increase of 0.01.
- For PBT Margin (%), as of Mar 25, the value is 11.40. This value is within the healthy range. It has increased from 8.97 (Mar 24) to 11.40, marking an increase of 2.43.
- For Net Profit Margin (%), as of Mar 25, the value is 7.94. This value is within the healthy range. It has increased from 5.43 (Mar 24) to 7.94, marking an increase of 2.51.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.83. This value is within the healthy range. It has increased from 6.20 (Mar 24) to 8.83, marking an increase of 2.63.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.74. This value is below the healthy minimum of 15. It has increased from 6.47 (Mar 24) to 8.74, marking an increase of 2.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.12. This value is below the healthy minimum of 10. It has increased from 8.46 (Mar 24) to 9.12, marking an increase of 0.66.
- For Return On Assets (%), as of Mar 25, the value is 4.20. This value is below the healthy minimum of 5. It has increased from 2.85 (Mar 24) to 4.20, marking an increase of 1.35.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.42, marking a decrease of 0.20.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.66. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.66, marking a decrease of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.47. It has increased from 0.45 (Mar 24) to 0.47, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.56, marking a decrease of 0.47.
- For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.31 (Mar 24) to 0.99, marking a decrease of 0.32.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.26. This value is within the healthy range. It has increased from 0.67 (Mar 24) to 4.26, marking an increase of 3.59.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 18.56. This value is below the healthy minimum of 20. It has decreased from 36.02 (Mar 24) to 18.56, marking a decrease of 17.46.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.52. This value is below the healthy minimum of 20. It has decreased from 18.86 (Mar 24) to 11.52, marking a decrease of 7.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 81.44. This value exceeds the healthy maximum of 70. It has increased from 63.98 (Mar 24) to 81.44, marking an increase of 17.46.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.48. This value exceeds the healthy maximum of 70. It has increased from 81.14 (Mar 24) to 88.48, marking an increase of 7.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.12. This value is within the healthy range. It has increased from 3.25 (Mar 24) to 5.12, marking an increase of 1.87.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 3. It has increased from 1.84 (Mar 24) to 2.95, marking an increase of 1.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,279.65. It has decreased from 1,416.65 (Mar 24) to 1,279.65, marking a decrease of 137.00.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.11. This value exceeds the healthy maximum of 3. It has decreased from 4.65 (Mar 24) to 4.11, marking a decrease of 0.54.
- For EV / EBITDA (X), as of Mar 25, the value is 19.69. This value exceeds the healthy maximum of 15. It has decreased from 22.03 (Mar 24) to 19.69, marking a decrease of 2.34.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 3.88 (Mar 24) to 3.43, marking a decrease of 0.45.
- For Retention Ratios (%), as of Mar 25, the value is 81.43. This value exceeds the healthy maximum of 70. It has increased from 63.97 (Mar 24) to 81.43, marking an increase of 17.46.
- For Price / BV (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has decreased from 4.05 (Mar 24) to 3.39, marking a decrease of 0.66.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 3.88 (Mar 24) to 3.43, marking a decrease of 0.45.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hester Biosciences Ltd:
- Net Profit Margin: 7.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.12% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.74% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.95
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.99
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 31.4 (Industry average Stock P/E: 42.92)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.66
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.94%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | �Pushpak� 1st Floor, Panchvati Circle, Ahmedabad Gujarat 380006 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Bhupendra Gandhi | Chairman |
| Mr. Rajiv Gandhi | Managing Director & CEO |
| Ms. Priya Gandhi | Executive Director |
| Mr. Ravin Gandhi | Director |
| Mr. Sanjiv Gandhi | Director |
| Mr. Ashok Bhadakal | Independent Director |
| Ms. Sandhya Patel | Independent Director |
| Mr. Ameet Desai | Independent Director |
| Mr. Anil Jain | Independent Director |
| Mr. Jatin Trivedi | Independent Director |
| Ms. Nina Gandhi | Alternate Director |
FAQ
What is the intrinsic value of Hester Biosciences Ltd?
Hester Biosciences Ltd's intrinsic value (as of 07 February 2026) is ₹940.00 which is 37.75% lower the current market price of ₹1,510.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,284 Cr. market cap, FY2025-2026 high/low of ₹2,350/1,243, reserves of ₹329 Cr, and liabilities of ₹675 Cr.
What is the Market Cap of Hester Biosciences Ltd?
The Market Cap of Hester Biosciences Ltd is 1,284 Cr..
What is the current Stock Price of Hester Biosciences Ltd as on 07 February 2026?
The current stock price of Hester Biosciences Ltd as on 07 February 2026 is ₹1,510.
What is the High / Low of Hester Biosciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hester Biosciences Ltd stocks is ₹2,350/1,243.
What is the Stock P/E of Hester Biosciences Ltd?
The Stock P/E of Hester Biosciences Ltd is 31.4.
What is the Book Value of Hester Biosciences Ltd?
The Book Value of Hester Biosciences Ltd is 397.
What is the Dividend Yield of Hester Biosciences Ltd?
The Dividend Yield of Hester Biosciences Ltd is 0.46 %.
What is the ROCE of Hester Biosciences Ltd?
The ROCE of Hester Biosciences Ltd is 9.71 %.
What is the ROE of Hester Biosciences Ltd?
The ROE of Hester Biosciences Ltd is 9.18 %.
What is the Face Value of Hester Biosciences Ltd?
The Face Value of Hester Biosciences Ltd is 10.0.